Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 2,590,000 shares, a decline of 94.6% from the March 31st total of 47,720,000 shares. Based on an average trading volume of 665,300 shares, the days-to-cover ratio is currently 3.9 days. Currently, 13.0% of the shares of the company are short sold.

Insider Activity

In other Agenus news, insider Garo H. Armen bought 25,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were acquired at an average cost of $13.00 per share, with a total value of $325,000.00. Following the acquisition, the insider now directly owns 31,298 shares of the company’s stock, valued at approximately $406,874. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Agenus

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Agenus in the third quarter valued at approximately $36,000. PCG Wealth Advisors LLC boosted its stake in shares of Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 18,850 shares during the last quarter. RPO LLC purchased a new position in shares of Agenus during the 4th quarter valued at approximately $43,000. Lindbrook Capital LLC boosted its stake in shares of Agenus by 38.8% during the 3rd quarter. Lindbrook Capital LLC now owns 52,535 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 14,674 shares during the last quarter. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in shares of Agenus during the 4th quarter valued at approximately $65,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Price Performance

NASDAQ:AGEN traded up $0.88 on Thursday, reaching $8.30. The stock had a trading volume of 960,558 shares, compared to its average volume of 628,664. The company has a market cap of $173.89 million, a price-to-earnings ratio of -0.56 and a beta of 1.26. The firm’s fifty day moving average is $11.06 and its two-hundred day moving average is $13.83. Agenus has a 12-month low of $4.78 and a 12-month high of $42.60.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The business had revenue of $83.80 million for the quarter, compared to the consensus estimate of $54.21 million. As a group, research analysts forecast that Agenus will post -8.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AGEN has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $160.00 price objective on shares of Agenus in a research note on Thursday, March 14th. B. Riley decreased their price objective on shares of Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 18th. Finally, StockNews.com initiated coverage on shares of Agenus in a research report on Wednesday, April 17th. They issued a “hold” rating on the stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.